Cargando…
Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
This study was to compare the efficacy and safety of combined glycoprotein IIb/IIIa inhibitor (GPI) and ticagrelor versus ticagrelor in patients with acute coronary syndrome (ACS). An observational study was conducted using the Improving Care for Cardiovascular Disease in China-ACS project. Totally,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853481/ https://www.ncbi.nlm.nih.gov/pubmed/33529262 http://dx.doi.org/10.1371/journal.pone.0246166 |
_version_ | 1783645970153603072 |
---|---|
author | Xie, Zhi-Jiang Xin, Shuan-Li Chang, Chao Zhou, Hai-Jing Zhao, Xiu-Feng Jiao, Feng-Hui Chen, Chuan Li, Tao |
author_facet | Xie, Zhi-Jiang Xin, Shuan-Li Chang, Chao Zhou, Hai-Jing Zhao, Xiu-Feng Jiao, Feng-Hui Chen, Chuan Li, Tao |
author_sort | Xie, Zhi-Jiang |
collection | PubMed |
description | This study was to compare the efficacy and safety of combined glycoprotein IIb/IIIa inhibitor (GPI) and ticagrelor versus ticagrelor in patients with acute coronary syndrome (ACS). An observational study was conducted using the Improving Care for Cardiovascular Disease in China-ACS project. Totally, 13,264 patients with ACS and received combination therapy or ticagrelor therapy were analyzed. The primary outcome was the composite of major cardiovascular events (MACE: all-cause mortality, myocardial infarction [MI], stent thrombosis, cardiogenic shock, and ischemic stroke), and secondary outcomes included all-cause mortality, MI, stent thrombosis, cardiogenic shock, and ischemic stroke. The multivariable adjusted analysis indicated that combination therapy was associated with an increased risk of major cardiovascular events (MACE) (P = 0.001), any bleeding (P<0.001), and major bleeding (P = 0.005). Moreover, the multivariable adjusted for propensity score-matched (PSM) analysis suggested that combination therapy produced additional risk of MACE (P = 0.014), any bleeding (P<0.001), and major bleeding (P = 0.005). Moreover, PSM analysis suggested that combination therapy was associated with greater risk of stent thrombosis (P = 0.012) and intracranial bleeding (P = 0.020). Combined GPI and ticagrelor therapies did not have any beneficial effects on MACE, stent thrombosis, intracranial bleeding, any bleeding, or major bleeding. |
format | Online Article Text |
id | pubmed-7853481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-78534812021-02-09 Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome Xie, Zhi-Jiang Xin, Shuan-Li Chang, Chao Zhou, Hai-Jing Zhao, Xiu-Feng Jiao, Feng-Hui Chen, Chuan Li, Tao PLoS One Research Article This study was to compare the efficacy and safety of combined glycoprotein IIb/IIIa inhibitor (GPI) and ticagrelor versus ticagrelor in patients with acute coronary syndrome (ACS). An observational study was conducted using the Improving Care for Cardiovascular Disease in China-ACS project. Totally, 13,264 patients with ACS and received combination therapy or ticagrelor therapy were analyzed. The primary outcome was the composite of major cardiovascular events (MACE: all-cause mortality, myocardial infarction [MI], stent thrombosis, cardiogenic shock, and ischemic stroke), and secondary outcomes included all-cause mortality, MI, stent thrombosis, cardiogenic shock, and ischemic stroke. The multivariable adjusted analysis indicated that combination therapy was associated with an increased risk of major cardiovascular events (MACE) (P = 0.001), any bleeding (P<0.001), and major bleeding (P = 0.005). Moreover, the multivariable adjusted for propensity score-matched (PSM) analysis suggested that combination therapy produced additional risk of MACE (P = 0.014), any bleeding (P<0.001), and major bleeding (P = 0.005). Moreover, PSM analysis suggested that combination therapy was associated with greater risk of stent thrombosis (P = 0.012) and intracranial bleeding (P = 0.020). Combined GPI and ticagrelor therapies did not have any beneficial effects on MACE, stent thrombosis, intracranial bleeding, any bleeding, or major bleeding. Public Library of Science 2021-02-02 /pmc/articles/PMC7853481/ /pubmed/33529262 http://dx.doi.org/10.1371/journal.pone.0246166 Text en © 2021 Xie et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Xie, Zhi-Jiang Xin, Shuan-Li Chang, Chao Zhou, Hai-Jing Zhao, Xiu-Feng Jiao, Feng-Hui Chen, Chuan Li, Tao Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome |
title | Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome |
title_full | Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome |
title_fullStr | Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome |
title_full_unstemmed | Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome |
title_short | Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome |
title_sort | combined glycoprotein iib/iiia inhibitor therapy with ticagrelor for patients with acute coronary syndrome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853481/ https://www.ncbi.nlm.nih.gov/pubmed/33529262 http://dx.doi.org/10.1371/journal.pone.0246166 |
work_keys_str_mv | AT xiezhijiang combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome AT xinshuanli combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome AT changchao combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome AT zhouhaijing combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome AT zhaoxiufeng combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome AT jiaofenghui combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome AT chenchuan combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome AT litao combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome |